Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microfluidic Point-of-Care Diagnostics Now a Must-Have

By LabMedica International staff writers
Posted on 27 May 2014
Yole Développement (Lyon, France) released its new, in-depth market research report – “Point of Care Testing 2014: Applications for Microfluidic Technologies.”

“Diagnostic companies confirm the adoption of microfluidic technologies for point-of-care testing”, said Dr. More...
Benjamin Roussel, Activity Leader, Medical Technologies, Yole Développement. Indeed the point-of-care(POC) market’s contribution to in vitro diagnostic is poised to increase from 13% to 17% over the next 5 years, leading to a market of around USD 30 billion in 2019. Under this context, the French consulting company Yole Développement released its report. Based on a complete analysis of the last 3 years’ developments, the company has been able to draw effective conclusions.

This technology and market study provides an in-depth analysis of microfluidic devices dedicated to POC; including nearly 60 new technologies, commercialized or close to market. Yole Développement’s report also proposes an innovative market segmentation combined with market forecasts. The analysis includes the following applications: emergency testing, home tests, doctor’s office screening, decentralized hospital tests, environmental testing, forensic and military, third-world infections, and agro-food applications.

“Different types of point of care tests are available on the market. Whereas simple lateral flow tests work perfectly without fluid management technology, microfluidics is necessary when test complexity increases,” said Dr. Roussel. Indeed, microfluidics is an enabling technology allowing miniaturization and integration of laboratory protocols into portable devices. Access to microfluidic technologies for diagnostic companies often passes through acquisitions, as this reduces the technology development risk and increases reactivity. The most recent acquisition was that of IQuum by Roche for USD 275 million in April 2014. In its new report, Yole Développement describes how mergers and acquisitions will decrease in volume but increase in value.

Microfluidic-based POC testing is expected to grow sharply, from USD 1.6 billion in 2013 to USD 5.6 billion in 2019, at a compound annual growth rate (CAGR) 2014–2019 of 23%. Diagnostics companies have realized the potential and several successful microfluidic POC products have been launched in the past few years.

Related Links:

Yole Développement



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.